Omnicell beat analysts’ revenue expectations by 2.2% last quarter, reporting revenues of $306.9 million, up 18.6% year on year. It was a slower quarter for the company, with EBITDA guidance for ...

Shares of healthcare tech company Omnicell (NASDAQ:OMCL) fell 17.5% in the afternoon session after the company reported weak first-quarter 2025 results, which featured full-year EPS and EBITDA ...

Omnicell (OMCL) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.03 per share a year ago. These figures ...

Omnicell, Inc. OMCL reported first-quarter 2025 adjusted earnings per share (EPS) of 26 cents compared with 3 cents in the year-ago period. The metric beat the Zacks Consensus Estimate by 62.5% ...

CEO Randall Lipps highlighted strong Q1 2025 performance driven by demand for Omnicell's medication management platform. Key focus areas included market share growth in inpatient and outpatient ...

Wells Fargo upgraded Omnicell (NASDAQ:OMCL) to Overweight from Equal Weight on Wednesday, citing a compelling risk-reward setup in the shares of the Fort Worth, Texas-based vendor of pharmacy ...

Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior ...

FORT WORTH, Texas (AP) — FORT WORTH, Texas (AP) — Omnicell Inc. (OMCL) on Tuesday reported a loss of $7 million in its first quarter. On a per-share basis, the Fort Worth, Texas-based company ...

Omnicell shares fell after the company lowered its guidance due to expected costs and uncertainty from tariffs. The stock slid 15% to $26.01 on Tuesday morning, at one point touching a 52-week low ...